A newly characterized metabolite in urine could one day help predict whether tuberculosis treatment is working or not. Concentration of the glycopeptide, which researchers believe is a metabolite of a protein called plasma protease C1 inhibitor — increase significantly in the urine of people with active pulmonary tuberculosis. In people who respond to treatment, metabolite levels dip back toward normal within a week (ACS Infect. Dis. 2018, DOI: 10.1021/acsinfecdis.8b00241). Though this initial study is small, such a test could help identify whether a candidate TB drug is likely to succeed or fail.
Items tagged with Scientific research
Molecule effective in killing tuberculosis bacteria (post)
A team of researchers affiliated with several institutions in the U.S. and one in France has found a molecule that is effective against tuberculosis. In their paper published in the journal Science, the group identifies the molecule and describes how well it worked when tested in vitro and in a mouse model. Valerie Mizrahi and Digby Warner with the University of Cape Town have authored a Perspective piece on the study in the same journal issue.
Tumour-related immunosuppression and treating persistent bacterial infections (post)
Dr Maija Hollmén at the University of Turku highlights the possibility of re-purposing macrophage stimulating cancer drugs to treat persistent bacterial infections, including TB.
Urine metabolite could signal tuberculosis treatment success (post)
New discovery could lead to ways to protect HIV patients from deadly TB (post)
Director of the Southwest National Primate Research Center Professor Deepak Kaushal, Ph.D. says research he collaborated on is pinpointing a possible new avenue of protection for HIV/AIDS patients. The study, published this month in the journal Cell Reports helps scientists better understand how HIV promotes deadly cases of tuberculosis (TB).
Tuberculosis: Inhibiting host cell death with immunotherapy (post)
Tuberculosis treatment still entails the intake several antibiotics over a period of many months and is torturous for many patients. The pathogen’s increasing multidrug resistance additionally complicates this lengthy treatment, and side effects frequently lead to a discontinuation of treatment and high mortality rates. Developing alternative treatment approaches is therefore of critical importance. DZIF scientists from the University Hospital Cologne are working on an immunotherapy that supports antibiotic treatment. In their current study, they were able to identify a new target protein in human immune cells, which can inhibit the bacteria’s destructive effects.
New TB drug may shorten treatment time for patients (post)
Washington, DC - February 11, 2019 - A new experimental antibiotic for tuberculosis has been shown to be more effective against TB than isoniazid, a decades-old drug which is currently one of the standard treatments. In mouse studies, the new drug showed a much lower tendency to develop resistance, and it remains in the tissues where the Mycobacterium tuberculosis bacteria reside for longer, killing them more effectively. The research is published February 11 in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.
Physicists develop a new method to identify antibiotic-resistant bacteria (post)
A team of physicists from Immanuel Kant Baltic State University have suggested a method to identify single antibiotic-resistant tuberculosis-causing bacteria. The new method detects the bacteria and evaluates their resistance to antibiotics without damaging the biological sample. The results of the first trial of the method were published in Data in Brief.
Cell death trigger in tuberculosis bacteria (post)
Tuberculosis (TB) is one of the top ten causes of death worldwide. In 2017, 10 million people around the world fell ill with TB and 1.3 million died. The genome of the bacterium that causes TB holds a special toxin-antitoxin system with spectacular action: once the toxin is activated, all bacterial cells die, stopping the disease. An international research team co-led by the Wilmanns group at EMBL in Hamburg investigated this promising feature for therapeutic targets. They now share the first high-resolution details of the system in Molecular Cell.
Scientists revolutionise treatment of tuberculosis (post)
New medical advances could revolutionise the ability to treat undetected tuberculosis (TB) thanks to an international team of scientists led by the University of St Andrews
ImmunoPrecise Antibodies collaborates with FIND to help advance new TB diagnostic test (post)
VICTORIA, February 19, 2019 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the publication of the results of a research collaboration project with the Foundation for Innovative New Diagnostics (FIND) where IPA developed rabbit monoclonal antibodies (mAbs) for assessment in FIND’s sensitive new immunoassay diagnostic test for tuberculosis (TB). IPA developed rabbit monoclonal antibodies, using its B cell Select platform, that recognize lipoarabinomannan (LAM), a lipopolysaccharide target and biomarker for TB that can be excreted in the urine of individuals with the disease. Two of these antibodies, when combined with others to form capture-detection pairs and a sensitive chemical detection reagent, were highly specific for LAM and sensitive enough to detect LAM in urine samples.
Page 37 of 74 · Total posts: 0
←First 36 37 38 Last→